Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

The new targeted therapy is designed to block KRAS, a protein that drives many pancreatic cancers, and its approval underscores the importance of clinical trials in advancing treatment options.

New FDA-cleared AI tool analyzes breast MRI scans to help doctors predict the risk of cancer returning years before it ...

Revolution Medicines' daraxonrasib is the first drug that can broadly tackle one of the main drivers of pancreatic cancer.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new targeted cancer drug offers a superior first-line treatment for aggressive ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new targeted treatment for pancreatic cancer has been approved by the FDA after impressive ...

As cancer survival rates climb, a quieter crisis has been growing alongside the victories: cancer-related pain. Roughly a ...

Five years ago, Lori Anderson's future looked bleak. Diagnosed with triple-negative breast cancer (TNBC), an aggressive form ...

The deadliest lung cancer has slipped past the body’s defenses for decades, and researchers now think they have found a way ...

When Casey Westlake had her first mammogram around a year ago, she was told everyone gets called back in. So when she was ...

A scoping review of five studies spanning five decades finds that root canal treatment in patients previously treated with ...